Immutep Limited (NASDAQ:IMMP) is a biotechnology company developing therapies for cancer and autoimmune diseases. The firm’s ...
In a boost for its phase III Indonesian diabetic foot infection trial, Recce becomes eligible for up to $85 million of ...
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel ...
The next few years of projected revenues in the pharma space have more holes in them than industry CEOs’ favorite golf ...
In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...
Detailed price information for Ventripoint Diagnostics Ltd (VPT-X) from The Globe and Mail including charting and trades.
Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanomaFive-year analysis of median progression free ...
The report is based on the experience of a patient with recurrent retroperitoneal DDLPS and is believed to be the first reported case in which such a patient achieved a pathological complete response ...
Immutep Ltd ( ($AU:IMM) ) just unveiled an announcement. Immutep Limited has announced significant progress in its global TACTI-004 (KEYNOTE-F91) ...
If approved, CUTX-101 will be the first and only FDA-approved treatment available for Menkes disease, a rare X-linked ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback